systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-309Research ArticleКАРДИОПУЛЬМОНОЛОГИЯОсобенности течения сердечно-сосудистых заболеваний и принципы выбора рациональной антигипертензивной терапии у больных хронической обструктивной болезнью легкихНапалковД. А.dminap@mail.ruПанферовА. С.a_panferov@mail.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииRussian Federation2013231220221037779Copyright © Напалков Д.А., Панферов А.С., 20222022Напалков Д.А., Панферов А.С.Напалков Д.А., Панферов А.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/309

В статье обсуждается взаимное влияние сердечно-сосудистой патологии и заболеваний, сопровождающихся бронхообструктивным синдромом. Особое внимание уделено выбору антигипертензивного препарата у пациентов с хронической обструктивной болезнью легких с учетом отсутствия четких рекомендаций по данному вопросу. Вновь акцентирована возможность применения кардиоселективных b-адреноблокаторов у больных данной группы без негативного влияния на показатели функции внешнего дыхания.

артериальная гипертензияхроническая обструктивная болезнь легкихбезопасностьb-адреноблокаторыReferencesTalikka M, Sierro N, Ivanov N.V et al. Genomic impact of cigarette smoke, with application to three smoking - related diseases. Critical Rev Toxicol 2012; 42 (10): 877–89.Talikka M, Sierro N, Ivanov N.V et al. Genomic impact of cigarette smoke, with application to three smoking - related diseases. Critical Rev Toxicol 2012; 42 (10): 877–89.Wilker E.H, Alexeeff S.E, Poon A et al. Candidate Genes for Respiratory Disease Associated with Markers of Inflammation and Endothelial Dysfunction in Elderly Men. Atherosclerosis 2009; 206 (2): 480–5.Wilker E.H, Alexeeff S.E, Poon A et al. Candidate Genes for Respiratory Disease Associated with Markers of Inflammation and Endothelial Dysfunction in Elderly Men. Atherosclerosis 2009; 206 (2): 480–5.Cui H, Miao D-M, Wei Z-M et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9: 5–10.Cui H, Miao D-M, Wei Z-M et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9: 5–10.Finkelstein J, Cha E, Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Intern J COPD 2009; 4: 337–49.Finkelstein J, Cha E, Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Intern J COPD 2009; 4: 337–49.Sidney S, Sorel M, Quesenberry C.P.Jr et al. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality: Kaiser Permanente Medical Care Program. CHEST 2005; 128: 2068–75.Sidney S, Sorel M, Quesenberry C.P.Jr et al. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality: Kaiser Permanente Medical Care Program. CHEST 2005; 128: 2068–75.Curkendall S.M, De Luise C, Jones J.K et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.Curkendall S.M, De Luise C, Jones J.K et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.Nussbaumer-Ochsner Y, Rabe K.F. Systemic Manifestations of COPD. CHEST 2011; 139 (1): 165–73.Nussbaumer-Ochsner Y, Rabe K.F. Systemic Manifestations of COPD. CHEST 2011; 139 (1): 165–73.Mirrakhimov A.E. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132–58.Mirrakhimov A.E. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132–58.Ekstrom M.P, Hermansson A.B, Strom K.E. Effect Of Cardiovascular Drugs On Mortality In Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. Am J Respir Crit Care Med 2012; 185: A2263.Ekstrom M.P, Hermansson A.B, Strom K.E. Effect Of Cardiovascular Drugs On Mortality In Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. Am J Respir Crit Care Med 2012; 185: A2263.Lawesa C.M.M, Thornleyb S, Youngc R et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21 (1): 35–40.Lawesa C.M.M, Thornleyb S, Youngc R et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21 (1): 35–40.Mortensen E.M, Copeland L.A, Pugh M.J.V et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10 (1): 45.Mortensen E.M, Copeland L.A, Pugh M.J.V et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10 (1): 45.Salpeter S.R, Ormiston T.M, Salpeter E.E. Cardioselective beta - blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005. Issue 4. Art. No.: CD003566. DOI: 10.1002/14651858.CD003566.Salpeter S.R, Ormiston T.M, Salpeter E.E. Cardioselective beta - blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005. Issue 4. Art. No.: CD003566. DOI: 10.1002/14651858.CD003566.Salpeter S.R, Ormiston T.M, Salpeter E.E et al. Cardioselective beta - blockers for reversible airway disease. Cochrane Database of Systematic Reviews 2002. Issue 4. Art. No.: CD002992. DOI: 10.1002/14651858.CD002992.Salpeter S.R, Ormiston T.M, Salpeter E.E et al. Cardioselective beta - blockers for reversible airway disease. Cochrane Database of Systematic Reviews 2002. Issue 4. Art. No.: CD002992. DOI: 10.1002/14651858.CD002992.Etminan M, Jafari S, Carleton B et al. Beta - blocker use and COPD mortality: a systematic review and meta - analysis. BMC Pulmonary Medicine 2012; 12: 48.Etminan M, Jafari S, Carleton B et al. Beta - blocker use and COPD mortality: a systematic review and meta - analysis. BMC Pulmonary Medicine 2012; 12: 48.Lechat P, Packer M, Chalon S et al. Clinical effects of beta - adrenergic blockade in chronic heart failure: a meta - analysis of double - blind, placebo - controlled, randomised trials. Circulation 1998; 98: 1184–91.Lechat P, Packer M, Chalon S et al. Clinical effects of beta - adrenergic blockade in chronic heart failure: a meta - analysis of double - blind, placebo - controlled, randomised trials. Circulation 1998; 98: 1184–91.Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730–7.Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730–7.Jabbour A, Macdonald P.S, Keogh A.M et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: a Randomized Crossover Trial. JACC 2010; 55 (17): 1780–7.Jabbour A, Macdonald P.S, Keogh A.M et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: a Randomized Crossover Trial. JACC 2010; 55 (17): 1780–7.Chatterjee S, Biondi-Zoccai G, Abbate A et al. Benefits of b - blockers in patients with heart failure and reduced ejection fraction: network meta - analysis. BMJ 2013; 346: f55.Chatterjee S, Biondi-Zoccai G, Abbate A et al. Benefits of b - blockers in patients with heart failure and reduced ejection fraction: network meta - analysis. BMJ 2013; 346: f55.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективных b - адреноблокаторов у пациентов с артериальной гипертонией и/или ИБС и сопутствующим бронхообструктивным синдромом. Тер. архив. 2007; 79 (9): 12–8.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективных b - адреноблокаторов у пациентов с артериальной гипертонией и/или ИБС и сопутствующим бронхообструктивным синдромом. Тер. архив. 2007; 79 (9): 12–8.Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество, 2012; с. 62–3.Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество, 2012; с. 62–3.Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Прил. 2.Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Прил. 2.Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). European Society of Hypertension Scientific Newsletter: Update on Hypretension Management 2012; 13: No. 51.Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). European Society of Hypertension Scientific Newsletter: Update on Hypretension Management 2012; 13: No. 51.Dart R.A, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003; 123: 222–43.Dart R.A, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003; 123: 222–43.Cazzola M, Noschese P, D’Amato G, Matera M.G. The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction. Chest 2002; 121: 230–41.Cazzola M, Noschese P, D’Amato G, Matera M.G. The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction. Chest 2002; 121: 230–41.Hill N.S. Fluid and Electrolyte Considerations in Diuretic Therapy for Hypertensive Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 1986; 146: 129–33.Hill N.S. Fluid and Electrolyte Considerations in Diuretic Therapy for Hypertensive Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 1986; 146: 129–33.Mancini G.B.J, Noschese P, D’Amato G, Matera M.G. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2006; 47: 2554–60.Mancini G.B.J, Noschese P, D’Amato G, Matera M.G. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2006; 47: 2554–60.Myou S, Fujimura M, Kamio Y et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med 2000; 162: 40–4.Myou S, Fujimura M, Kamio Y et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med 2000; 162: 40–4.Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.Toblli J.E, Di Gennaro F, Giani J.F et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular Health Risk Management 2012; 8: 151–60.Toblli J.E, Di Gennaro F, Giani J.F et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular Health Risk Management 2012; 8: 151–60.Капустина В.А., Овчаренко С.И., Литвицкий П.Ф. Влияние длительной антиоксидантной терапии N-ацетилцистеином на показатели оксидативного стресса у больных хронической обструктивной болезнью легких. Фарматека. 2010; 20: 84–9.Капустина В.А., Овчаренко С.И., Литвицкий П.Ф. Влияние длительной антиоксидантной терапии N-ацетилцистеином на показатели оксидативного стресса у больных хронической обструктивной болезнью легких. Фарматека. 2010; 20: 84–9.Akçay A, Acar G, Kurutaş E et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars 2010; 38 (4): 244–9.Akçay A, Acar G, Kurutaş E et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars 2010; 38 (4): 244–9.Kus K, Gajda M, Pyka-Fosciak G et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60 (4): 163–5.Kus K, Gajda M, Pyka-Fosciak G et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60 (4): 163–5.

The authors declare that there are no conflicts of interest present.